Cargando…
Are we ready to use anti-amyloid therapy in Alzheimer's disease?
Alzheimer’s disease (AD) is the most common neurodegenerative disease. Biomarkers have demonstrated that AD pathology exists over the disease continuum from a stage preceding symptoms over 15-25 years to the progressively more impaired symptomatic states, mild cognitive impairment (MCI), and dementi...
Autores principales: | Brucki, Sonia Maria Dozzi, César-Freitas, Karolina Gouveia, Spera, Raphael Ribeiro, Borges, Conrado Regis, Smid, Jerusa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491439/ https://www.ncbi.nlm.nih.gov/pubmed/35976307 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S117 |
Ejemplares similares
-
Normal pressure hydrocephalus: an update
por: Passos-Neto, Carlos Eduardo Borges, et al.
Publicado: (2022) -
Analysis of macrolinguistic aspects of narratives from individuals with Alzheimer's disease, mild cognitive impairment, and no cognitive impairment
por: Toledo, Cíntia Matsuda, et al.
Publicado: (2017) -
From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias
por: Studart-Neto, Adalberto, et al.
Publicado: (2022) -
How to differentiate behavioral variant frontotemporal dementia from primary psychiatric disorders: practical aspects for the clinician
por: Gambogi, Leandro Boson, et al.
Publicado: (2022) -
Genetic investigation of dementias in clinical practice
por: Takada, Leonel Tadao
Publicado: (2022)